Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GridAI TechnologiesGRDX +1.08%26 PB Ratio is 1.31 as of Aug. 19, 2026, which is 38% above its 10-year median of 0.95. GuruFocus rates GRDX with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,216 Biotechnology companies, GridAI Technologies ranks better than 77.06% on this metric.
The historical rank and industry rank for GridAI Technologies's PB Ratio or its related term are showing as below:
GRDX'
s PB Ratio Range Over the Past 10 Years
Min: 0.44 Med: 0.95 Max: 2.09
Current: 1.27
During the past 12 years, GridAI Technologies's highest PB Ratio was 2.09. The lowest was 0.44. And the median was 0.95.
GRDX's PB Ratio is ranked better than 77.06% of 1216
companies
in the Biotechnology industry
Industry Median: 2.895
vs GRDX: 1.27
During the past 3 years, the average Book Value Per Share Growth Rate was -69.20% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of GridAI Technologies was 93.20% per year. The lowest was -69.20% per year. And the median was 12.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
GridAI Technologies PB Ratio Related Terms
GridAI Technologies PB Ratio Historical Data
* Premium members only.
The historical data trend for GridAI Technologies's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, GridAI Technologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GridAI Technologies PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GridAI Technologies's PB Ratio distribution charts can be found below:
* The bar in red indicates where GridAI Technologies's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
GridAI Technologies (GRDX) has a PB Ratio of 1.31 as of Aug. 19, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GridAI Technologies and its competitors. This is 38% above median its historical median of 0.95. Over the past decade, GridAI Technologies' PB Ratio has ranged from 0.44 to 2.09. According to the industry distribution chart, GridAI Technologies ranks #279 out of 1216 companies in the Biotechnology industry, placing it in the top 22.9%.
Is GridAI Technologies' PB Ratio too high?
GridAI Technologies' current PB Ratio of 1.31 is 38% above median its 10-year median of 0.95. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 2.09. The Biotechnology industry median PB Ratio is 2.90. GridAI Technologies' value of 1.31 is 54.7% below this industry median. Based on the distribution chart, GridAI Technologies ranks #279 out of 1216 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GridAI Technologies has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does GridAI Technologies' PB Ratio compare to CELU and NRSN?
According to the Biotechnology industry distribution chart, GridAI Technologies ranks #279 out of 1216 companies for PB Ratio. This places GridAI Technologies in the top 23% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.90. GridAI Technologies' value of 1.31 is 54.7% below this benchmark. Historically, GridAI Technologies' own PB Ratio has ranged from 0.44 to 2.09 over the past decade. While the company's 10-year median is 0.95 vs. the industry median of 2.90, GridAI Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,216 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GridAI Technologies's current PB Ratio of 1.31 is 54.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GridAI Technologies and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GridAI Technologies's current PB Ratio is 1.31, which is 38% above median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GridAI Technologies stock overvalued right now?
GridAI Technologies (GRDX) has a current PB Ratio of 1.31. The current PB Ratio is 1.31, which is 38% above median its 10-year median of 0.95 and 54.7% below the Biotechnology industry median of 2.90. GridAI Technologies' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For GridAI Technologies (GRDX), the current PB Ratio is 1.31 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
26GF Score
Get the complete analysis for GRDX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRDX has been successfully added to your 
